Vaccines’ New Era-RNA Vaccine
Author:
Zhou Wenshuo1ORCID, Jiang Linglei1, Liao Shimiao1ORCID, Wu Feifei1, Yang Guohuan1ORCID, Hou Li1ORCID, Liu Lan1ORCID, Pan Xinping1, Jia William12ORCID, Zhang Yuntao13
Affiliation:
1. CNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China 2. Shanghai-Virogin Biotech Co., Ltd., Shanghai 201800, China 3. Sinopharm Group China National Biotech Group (CNBG) Co., Ltd., Beijing 100124, China
Abstract
RNA vaccines, including conventional messenger RNA (mRNA) vaccines, circular RNA (circRNA) vaccines, and self-amplifying RNA (saRNA) vaccines, have ushered in a promising future and revolutionized vaccine development. The success of mRNA vaccines in combating the COVID-19 pandemic caused by the SARS-CoV-2 virus that emerged in 2019 has highlighted the potential of RNA vaccines. These vaccines possess several advantages, such as high efficacy, adaptability, simplicity in antigen design, and the ability to induce both humoral and cellular immunity. They also offer rapid and cost-effective manufacturing, flexibility to target emerging or mutant pathogens and a potential approach for clearing immunotolerant microbes by targeting bacterial or parasitic survival mechanisms. The self-adjuvant effect of mRNA-lipid nanoparticle (LNP) formulations or circular RNA further enhances the potential of RNA vaccines. However, some challenges need to be addressed. These include the technology’s immaturity, high research expenses, limited duration of antibody response, mRNA instability, low efficiency of circRNA cyclization, and the production of double-stranded RNA as a side product. These factors hinder the widespread adoption and utilization of RNA vaccines, particularly in developing countries. This review provides a comprehensive overview of mRNA, circRNA, and saRNA vaccines for infectious diseases while also discussing their development, current applications, and challenges.
Funder
Shanghai Science and Technology Plan 2022, the 4th batch of an emergency special projects Shanghai, the 18th batch of strategic emerging Industry Development special fund project Establishment of high-throughput mRNA screening automation and platform
Subject
Virology,Infectious Diseases
Reference113 articles.
1. The Tangled History of MRNA Vaccines;Dolgin;Nature,2021 2. BNT162b Vaccines Protect Rhesus Macaques from SARS-CoV-2;Vogel;Nature,2021 3. Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation;Wrapp;Science,2020 4. Sanders, R.W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H.J., Blattner, C., de la Peña, A.T., and Korzun, J. (2013). A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP. 664 Gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. PLoS Pathog., 9. 5. RNA Is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine;Hayashi;Sci. Rep.,2016
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|